News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|November 24, 2020

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Author(s)Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, Robert Naismith, MD, Bianca Weinstock-Guttman, MD

Episodes in this series

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Esther Bui, MD

Issues Surrounding Reproductive Health in Women with Epilepsy: Esther Bui, MD

ByEsther Bui, MD,Louie Pasculli

December 8th 2025

Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD

ByJoseph Sullivan, MD,Marco Meglio

December 8th 2025

Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care

ByMarco Meglio,Sharon Hesterlee, PhD

December 8th 2025

Stephane Auvin, MD, PhD

Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows

ByLouie Pasculli

December 8th 2025

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study

December 8th 2025

Latest CME

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic

Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome

© 2025 MJH Life Sciences^®

All rights reserved.